Effects of Raloxifene and their Combination with Pioglitazone on Serum Anti-Mullerian Hormone Levels in Patients with Resistance Polycystic Ovary Syndrome

被引：0

作者：

Kutaif, Rana Hussein ^{[1
]}

Alabbassi, Mustafa G. ^{[2
]}

Hussein, Weqar Akram ^{[3
]}

Aldujaili, Alla Abdul-Mehdi ^{[4
]}

Ali, Zainab Faleh ^{[5
]}

Jassim, Shatha Khayun ^{[5
]}

机构：

[1] Al Turath Univ Coll, Dept Pharm, Baghdad, Iraq

[2] Univ Alkafeel, Coll Pharm, Dept Pharmacol & Toxicol, Kufa, Iraq

[3] Baghdad Univ, Coll Al Kindi Med, Obstet & Gynecol Dept, Baghdad, Iraq

[4] Minist Hlth, Baghdad, Iraq

[5] Al Haj Jalal Hosp, Obstet & Gynecol Dept, Wasit, Iraq

来源：

LATIN AMERICAN JOURNAL OF PHARMACY | 2021年 / 40卷 / SI期

关键词：

anti-mullerian hormone; ovulation induction; PCOS; pioglitazone; raloxifene; INSULIN-RESISTANCE; INHIBITING SUBSTANCE; WOMEN; METFORMIN; HYPERANDROGENISM; MARKER;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the ovary of humans, anti-Mullerian hormone (AMH) is expressed in the granulose cells of prenatal follicles and small antral follicles. This study aimed to evaluate the effect of raloxifene alone and their combination with pioglitazone, for 12 weeks, on serum AMH levels in overweight women with resistance polycystic ovary. Sixty-four overweight women with polycystic ovary syndrome, patients in (Group 1) received raloxifene 60 mg oral tablets twice daily for 5 days starting on the 3rd day of spontaneous or progesterone-induced withdrawal bleeding, and patients in (Group 2) received raloxifene 60 mg twice daily for 5 days each month plus pioglitazone oral tablets 15 mg once per day for one week, followed by 2 tablets/day to complete 12 weeks.AMH level was significantly increased after treatment in both groups. Significant changes in AMH level were observed during ovulation induction, when used of raloxifene and combination therapy. In conclusion, the serum AMH increases in overweight women with PCOS after raloxifene and combination therapy for 12 weeks of treatment. AMH level was useful to predict a patient's response to treatment in women with resistance PCOS.

引用

页码：76 / 81

页数：6

共 38 条

[1]

Al-Obaidi Z.M.J., 2018, J PHARM SCI RES, V10, P1464

[2] ANTI-MULLERIAN HORMONE AS A DIAGNOSTIC MARKER IN EGYPTIAN INFERTILE POLYCYSTIC OVARY SYNDROME FEMALES: CORRELATIONS WITH VITAMIN D, TOTAL TESTOSTERONE, DYSLIPIDEMIA AND ANTHROPOMETRIC PARAMETERS [J].